Fusion protein
US8309096B2 · kind B2 · utility
7Cited by
13References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 15, 2009 |
| Grant date | Nov 13, 2012 |
| Priority date | — |
| Expiry date | Dec 5, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/42
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.